Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 9019 results

  1. Remedē System (Respicardia Inc) for transvenous stimulation of the phrenic nerve towards the tehrapy of Central sleep apnoea - moderate to severe

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Full Endoscopic Spine Surgery

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Eptinezumab for preventing cluster headache attacks TSID 12087

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Reinforcement of a permanent stoma with synthetic or biological mesh to prevent a parastomal hernia

    Awaiting development Reference number: GID-HTG10678 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  11. Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Remibrutinib for treating chronic inducible urticaria inadequately controlled by H1-antihistamines [ID6742]

    Awaiting development Reference number: GID-TA11968 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]

    Awaiting development Reference number: GID-TA11936 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pharmalgen for the treatment of bee and wasp venom allergy

    In development Reference number: GID-TA11898 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation